Percutaneous Intraductal Radiofrequency Ablation is a Safe Treatment for Malignant Biliary Obstruction: Feasibility and Early Results

Journal Article · Sat Jun 15 04:00:00 EDT 2013 · Cardiovascular and Interventional Radiology

DOI:https://doi.org/10.1007/S00270-012-0529-3· OSTI ID:22113642

Mizandari, Malkhaz ^[1]; Pai, Madhava; Feng, Xi ^[2]; Valek, Vlastimil; Tomas, Andrasina ^[3]; Quaretti, Pietro ^[4]; Golfieri, Rita; Mosconi, Cristina ^[5]; Guokun, Ao ^[6]; Kyriakides, Charis ^[2]; Dickinson, Robert ^[7]; Nicholls, Joanna; Habib, Nagy ^[2]

---

1. Tbilisi State Medical University, Department of Radiology (Georgia)
2. Imperial College, London, Hammersmith Hospital Campus, Department of Surgery (United Kingdom)
3. University Hospital Brno Bohunice, Department of Radiology (Czech Republic)
4. IRCCS Policlinico San Matteo, Department of Radiology (Italy)
5. University of Bologna, Department of Radiology, Policlinico S. Orsola-Malpighi (Italy)
6. The 309 Hospital of Chinese PLA, Department of Radiology (China)
7. Imperial College London, Department of Bioengineering (United Kingdom)

Purpose. Previous clinical studies have shown the safety and efficacy of this novel radiofrequency ablation catheter when used for endoscopic palliative procedures. We report a retrospective study with the results of first in man percutaneous intraductal radiofrequency ablation in patients with malignant biliary obstruction. Methods. Thirty-nine patients with inoperable malignant biliary obstruction were included. These patients underwent intraductal biliary radiofrequency ablation of their malignant biliary strictures following external biliary decompression with an internal-external biliary drainage. Following ablation, they had a metal stent inserted. Results. Following this intervention, there were no 30-day mortality, hemorrhage, bile duct perforation, bile leak, or pancreatitis. Of the 39 patients, 28 are alive and 10 patients are dead with a median survival of 89.5 (range 14-260) days and median stent patency of 84.5 (range 14-260) days. One patient was lost to follow-up. All but one patient had their stent patent at the time of last follow-up or death. One patient with stent blockage at 42 days postprocedure underwent percutaneous transhepatic drain insertion and restenting. Among the patients who are alive (n = 28) the median stent patency was 92 (range 14-260) days, whereas the patients who died (n = 10) had a median stent patency of 62.5 (range 38-210) days. Conclusions. In this group of patients, it appears that this new approach is feasible and safe. Efficacy remains to be proven in future, randomized, prospective studies.

• OSTI ID: 22113642
• Journal Information: Cardiovascular and Interventional Radiology, Journal Name: Cardiovascular and Interventional Radiology Journal Issue: 3 Vol. 36; ISSN 0174-1551; ISSN CAIRDG
• Country of Publication: United States
• Language: English

Related Subjects

62 RADIOLOGY AND NUCLEAR MEDICINE
ABLATION
BILE
BILIARY TRACT
DIGESTIVE SYSTEM DISEASES
HEMORRHAGE
MORTALITY
NEOPLASMS
PANCREAS
PATENTS
PATIENTS
RADIOWAVE RADIATION